Raymond James Maintains Strong Buy on Dyne Therapeutics, Raises Price Target to $56
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has reaffirmed a Strong Buy rating on Dyne Therapeutics (NASDAQ:DYN) and increased the price target from $27 to $56.
January 04, 2024 | 9:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James analyst Steven Seedhouse maintains a Strong Buy rating on Dyne Therapeutics and raises the price target from $27 to $56.
The reaffirmation of a Strong Buy rating coupled with a significant increase in the price target from $27 to $56 by a reputable analyst at Raymond James is likely to instill confidence in investors and could lead to a short-term increase in the stock price of Dyne Therapeutics.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100